- Home
- IKNA vs QNCX Comparison
IKNA vs QNCX Comparison
Compare IKNA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- QNCX
- Stock Information
- Founded
- IKNA 2016
- QNCX 2012
- Country
- IKNA United States
- QNCX United States
- Employees
- IKNA N/A
- QNCX N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IKNA Health Care
- QNCX Health Care
- Exchange
- IKNA Nasdaq
- QNCX Nasdaq
- Market Cap
- IKNA 81.6M
- QNCX 70.4M
- IPO Year
- IKNA 2021
- QNCX 2019
- Fundamental
- Price
- IKNA $1.45
- QNCX $1.54
- Analyst Decision
- IKNA Buy
- QNCX Strong Buy
- Analyst Count
- IKNA 2
- QNCX 4
- Target Price
- IKNA $3.00
- QNCX $9.50
- AVG Volume (30 Days)
- IKNA 134.5K
- QNCX 126.5K
- Earning Date
- IKNA 03-11-2025
- QNCX 11-13-2024
- Dividend Yield
- IKNA N/A
- QNCX N/A
- EPS Growth
- IKNA N/A
- QNCX N/A
- EPS
- IKNA N/A
- QNCX N/A
- Revenue
- IKNA $659,000.00
- QNCX N/A
- Revenue This Year
- IKNA N/A
- QNCX N/A
- Revenue Next Year
- IKNA N/A
- QNCX N/A
- P/E Ratio
- IKNA N/A
- QNCX N/A
- Revenue Growth
- IKNA N/A
- QNCX N/A
- 52 Week Low
- IKNA $1.22
- QNCX $0.51
- 52 Week High
- IKNA $1.94
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- IKNA 36.12
- QNCX 43.31
- Support Level
- IKNA $1.45
- QNCX $1.58
- Resistance Level
- IKNA $1.53
- QNCX $1.69
- Average True Range (ATR)
- IKNA 0.06
- QNCX 0.12
- MACD
- IKNA -0.00
- QNCX -0.01
- Stochastic Oscillator
- IKNA 23.53
- QNCX 51.28
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.